Back
LQR House Vs. Sarepta Therapeutics Industry Stock Comparison
Sell
48
LQR
LQR House
Last Price:
0.91
Seasonality Move:
1.31%
Sell
49
SRPT
Sarepta Therapeutics
Last Price:
138.01
Seasonality Move:
14.88%
Sell
48
LQR House (LQR)
is a Sell
Is LQR House a Buy, Sell or Hold?
- The current LQR House [LQR] share price is $0.90. The Score for LQR is 48, which is 4% below its historic median score of 50, and infers higher risk than normal.
- LQR is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
49
Sarepta Therapeutics (SRPT)
is a Sell
Is Sarepta Therapeutics a Buy, Sell or Hold?
- The current Sarepta Therapeutics [SRPT] share price is $130.50. The Score for SRPT is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.
- SRPT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
LQR Stock Price Chart
SRPT Stock Price Chart
What is Sarepta Therapeutics's stock price today?
-
The Sarepta Therapeutics share price today is $130.50
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SRPT is experiencing buying pressure, which is a positive indicator for future bullish movement.
LQR Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.12 | Buy |
| Relative Strength Index (14 RSI): | 50.63 | Buy |
| Chaikin Money Flow: | -196797 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | ( - ) | Buy |
| Bollinger Bands (100): | ( - ) | Buy |
SRPT Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -2.3 | Sell |
| Relative Strength Index (14 RSI): | 64.59 | Buy |
| Chaikin Money Flow: | 3149400 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | ( - ) | Buy |
| Bollinger Bands (100): | ( - ) | Buy |
LQR Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 1.12 | Sell |
| 20-day SMA: | 0.91 | Sell |
| 50-day SMA: | 0.7 | Buy |
| 200-day SMA: | 0.98 | Sell |
| 8-day EMA: | 1.04 | Sell |
| 20-day EMA: | 0.94 | Sell |
| 50-day EMA: | 0.8 | Buy |
| 200-day EMA: | 3.32 | Sell |
SRPT Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 112.07 | Buy |
| 20-day SMA: | 117.27 | Buy |
| 50-day SMA: | 121.92 | Buy |
| 200-day SMA: | 129.99 | Buy |
| 8-day EMA: | 116.28 | Buy |
| 20-day EMA: | 117.14 | Buy |
| 50-day EMA: | 121.91 | Buy |
| 200-day EMA: | 125.98 | Buy |
LQR House Earnings Growth & LQR Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.05 per share, a decrease next quarter of $0.00 per share, an increase this year of $19.10 per share, and an increase next year of $0.30 per share.
Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates
- Analysts estimate an earnings increase this quarter of $2.75 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.84 per share, and an increase next year of $7.74 per share.
LQR House Technical Analysis
| Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | Nov 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | 27 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Sarepta Therapeutics Technical Analysis
| Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | Nov 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | 27 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||